Restoring Bioenergetics in the Traumatized Eye: The Emergence of Mitochondrial Implantation as a Treatment for Acute Ocular Injury
Aqueous Outflow Pathways (Trabecular Meshwork): No direct organelle rescue demonstrated.
Photoreceptors: Direct in vivo functional integration in outer retinal layers following isolated organelle delivery remains limited and unproven.
Secondary Traumatic Complications: Distinct mechanical shockwave injuries (such as commotio retinae) must be uncoupled from vascular I/R models. Furthermore, ocular siderosis represents a delayed chemical toxicity resulting from retained iron foreign bodies rather than an immediate acute trauma target [56].
The workflow for preparing MSC-derived mitochondria involves three critical phases: Isolation and Expansion, Mitochondrial Extraction, and Quality Control.
MSC Isolation and Expansion (The Source): MSCs can be isolated from several tissue sources, including bone marrow, adipose tissue, umbilical cord tissue, and urine-derived stem cells [57]. Following isolation, MSCs are cultured under controlled conditions and expanded to generate sufficient cellular biomass for mitochondrial harvesting. Expansion is typically limited to early passages (approximately 3–5) to minimize cellular senescence and preserve mitochondrial function [58]. Maintaining low-passage MSC populations is important, as prolonged culture can impair oxidative phosphorylation efficiency and increase mitochondrial dysfunction.
Mitochondrial Extraction (The Product): Once MSC cultures reach approximately 80–90% confluence, mitochondria are isolated while preserving membrane integrity and respiratory capacity [59]. Differential centrifugation remains the most widely utilized method for mitochondrial extraction due to its relative simplicity and ability to generate highly enriched mitochondrial fractions.
Initially, MSCs are homogenized in an isotonic, sucrose-based isolation buffer to disrupt the plasma membrane while maintaining mitochondrial structural integrity [60]. The homogenate subsequently undergoes sequential centrifugation steps. Low-speed centrifugation removes nuclei and cellular debris, while higher-speed centrifugation pellets mitochondria. The resulting mitochondrial fraction is purified and resuspended in cold respiration-supporting buffer (e.g., MiR05) to preserve membrane potential and metabolic activity until transplantation [61]. Preservation of the outer and inner mitochondrial membranes throughout extraction is critical, as disruption of membrane integrity impairs oxidative phosphorylation and ATP generation capacity.
Quality Control (The Validation): Prior to transplantation, isolated mitochondria must undergo rigorous quality control to confirm their viability, purity, and bioenergetic competence [62]. Functional validation commonly includes assessment of the oxygen consumption rate (OCR) using Seahorse XF analysis, which evaluates mitochondrial respiratory activity and oxidative phosphorylation capacity [63]. In parallel, mitochondrial membrane potential is measured using fluorescent probes such as JC-1 staining, providing insight into membrane polarization and overall organelles viability [64]. Purity analyses are also performed to verify enrichment of mitochondrial fractions while excluding contamination from other cellular organelles. This is commonly achieved through Western blotting for mitochondrial markers such as TOM 20 or COX IV, alongside the absence of non-mitochondrial proteins such as Calnexin, an endoplasmic reticulum marker [65]. Collectively, these quality control measures ensure that transplanted mitochondria retain sufficient structural integrity and metabolic function to appropriately support cellular recovery following acute ocular injury.
Overall, laboratory processing of MSC-derived mitochondria represents a scalable pipeline for mitochondrial therapeutics. Continued refinement of these protocols will be essential for improving reproducibility and advancing clinical translation.
Stem cell therapy, exosome or EV therapy, and mitochondrial transplantation address distinct pathological processes following acute ocular injury. When comparing these three modalities, transplantation of MSC-derived mitochondria proves advantageous due to a safety profile similar to that of exosome therapy, as isolated mitochondria lack nuclei and hence can’t form tumors [66], and the ability to provide immediate bioenergetic intervention critical due to the time-sensitive nature of acute ocular injury-triggered metabolic cascades that lead to permanent vision loss (Table 4 and Table 5).
Stem Cell Therapy: Stem cell therapies are a viable strategy due to their capacity for long-term survival within damaged tissues and continued secretion of growth factors [68]. Unlike acellular therapies, MSCs possess multipotent capabilities. Hence, they can contribute to regeneration of injured corneal and retinal structures in cases of severe trauma. However, these advantages are accompanied by notable limitations. Whole-cell transplantation carries risks associated with uncontrolled proliferation, aberrant differentiation, and tumorigenesis [69]. Furthermore, logistical challenges related to cell preservation, storage, and transplantation further complicate clinical implementation [70].
Exosome Therapy: Exosome therapies represent a cell-free alternative that functions primarily through intercellular signaling and immunomodulation [71,72]. As exosomes lack proliferative capacity, they offer improved safety with minimal risk of tumor formation. Their nanoscale size facilitates penetration through ocular barriers, enabling efficient delivery of proteins, lipids, and regulatory RNAs that mitigate inflammation and promote tissue repair [73]. They are also particularly efficient at mitigating cytokine storms [74]. Nevertheless, exosomes are unable to directly replace damaged tissue, instead relying on surviving host cells to mediate repair processes. Additionally, rapid clearance by lymphatic system may limit therapeutic duration, causing repeated administration to sustain beneficial effects [75].
Mitochondrial Transplantation: Mitochondrial transplantation distinguishes itself from other regenerative modalities by directly addressing cellular bioenergetic dysfunction [76]. In acute ocular injury, cells undergo rapid degeneration. Transplanted mitochondria may restore metabolic capacity, stabilize membrane potential, and reduce apoptotic signaling, hence preserving RGC before irreversible injury occurs. Similar to exosome therapies, isolated mitochondria provide a cell-free intervention. Moreover, mitochondrial therapies exhibit an exceptionally rapid onset of action, potentially restoring cellular metabolism shortly after administration [77]. Despite these advantages, mitochondrial transplantation faces important challenges. Isolated mitochondria are very fragile outside the intracellular environment [78]. Standardization of dosing, delivery efficiency, and long-term functional outcomes also remains unclear, highlighting the need for continued investigation before widespread clinical adoption.
The success of mitochondrial transplantation is influenced mainly by its delivery route, processing methods, and the biological characteristics of the donor cell source. To date, adipose-derived mesenchymal stem cells (AD-MSCs) and bone marrow-derived mesenchymal stem cells (BM-MSCs) have served as the main reservoirs for mitochondrial isolation due to their established clinical use and high cellular yield [79]. Adipose tissue offers a substantial initial biomass, allowing for efficient harvesting of mitochondria from large numbers of MSCs post liposuction. Bone marrow-derived MSCs remain a well-characterized source but require invasive aspiration and tend to exhibit lower stem cell frequency compared to adipose tissue.
Recently, placental and umbilical cord-derived MSCs have gained attention as alternative donor sources due to their developmental immaturity and low accumulation of mtDNA damage [80]. Mitochondria derived from these tissues may exhibit enhanced respiratory capacity and reduced oxidative burden relative to adult-derived sources. This suggests potential advantages for regenerative applications requiring maximal bioenergetic performance.
In contrast to other donors, urine-derived stem cells (USCs) are a particularly accessible and minimally invasive alternative [81]. USCs can be obtained repeatedly through routine urine collection without surgical intervention. This accessibility raises the possibility of creating patient-specific mitochondrial repositories and therapies. Furthermore, repeated collection enables longitudinal sampling, potentially allowing optimization of donor mitochondrial quality prior to transplantation.
While traditional sources have established benchmarks for mitochondrial yield, USCs are emerging as a highly promising, non-invasive and autologous alternative. Though comparative studies are currently limited, early research suggests that USCs offer unique metabolic advantages and bypass allogeneic rejection that could redefine personalized regenerative medicine.
1. Scalability and Proliferative Power: A primary consideration in donor source selection is the balance between initial mitochondrial yield and long-term scalability. Adipose-derived MSC provide exceptionally high starting biomass, enabling rapid isolation of large mitochondrial quantities with minimal expansion requirements [82]. While USCs populations initially have fewer stem cells but possess improved proliferative potential in proper culture. Following expansion, USC cultures may generate therapeutically relevant mitochondrial quantities while preserving the advantage of recipient-specificity and repeated, non-invasive collection.
2. Intrinsic Transfer Capacity: Effective mitochondrial transplantation depends not only on mitochondrial abundance but also on the ability of donor cells to support organelle transfer and uptake. Proteins such as Miro1, involved in mitochondrial trafficking, and Connexin-43 (Cx43), involved in intercellular transfer mechanisms, have been associated with enhanced mitochondrial transfer efficiency in MSC populations [83]. Although AD-MSCs and BM-MSCs have established transfer capabilities, little is known about expression profiles for USC populations. Given their distinctive metabolic phenotype and secretory characteristics, USCs may exhibit unique transfer kinetics and altered interactions with recipient tissues. Future investigations comparing Miro1 and Cx43 expression among donor sources could clarify whether USC-derived autologous mitochondria possess enhanced therapeutic target potential without untoward immunogenicity.
3. Mitochondrial Fitness and Donor Optimization: Placental and umbilical cord-derived tissues provide “young” mitochondria characterized by lower cumulative oxidative damage and reduced mtDNA mutation burden. However, these sources are limited by availability and reduced suitability for autologous transplantation. USCs may offer a distinct advantage through compatibility with personalized autologous therapies, minimizing immune incompatibility while enabling repeated donor sampling. As USC populations require expansion prior to therapeutic application, this culture period presents the opportunity for mitochondrial preconditioning strategies designed to optimize respiratory function, stress resistance, or metabolic performance before transplantation.
4. The “Time-to-Dose” Evolution: Traditional donor sources may provide shorter time-to-dose intervals due to immediate availability of large tissue volumes. In contrast, USC-derived therapies generally require an expansion period before sufficient mitochondrial quantities are obtained. Although this delay may reduce utility in emergency interventions, it may prove advantageous for planned or personalized treatments. Consequently, the optimal donor source may depend less on absolute superiority and more on clinical context. Acute emergencies may favor immediately available adipose-derived mitochondria, whereas chronic or personalized applications may benefit from the scalability and accessibility of USCs.
While the therapeutic potential of MSC-derived mitochondrial transplantation is immense, several hurdles must be addressed to transition this therapy from the laboratory to the clinic. Mitochondria are highly sensitive organelles that when isolated begin to lose functional viability rapidly if not kept on ice in specialized buffers. Preservation of mitochondrial integrity during storage and transport is a significant translational barrier. Developing cryopreservation techniques is necessary to tackle this issue. Lyophilization, nanocarrier encapsulation, and biomaterial-assisted stabilization are currently being investigated as methods to prolong mitochondrial functionality and improve delivery efficiency.
Another major challenge is the lack of standardized dosing metrics for mitochondrial therapies. In conventional pharmacology, dosing is typically quantified in milligrams, whereas cell therapies rely on total cell counts. By contrast, mitochondrial transplantation lacks a universally accepted unit capable of correlating quantity with therapeutic efficacy. Establishing a reproducible potency assay will be critical for ensuring consistent clinical outcomes across patient populations and types of injury.
Additionally, confirming successful mitochondrial uptake and long-term persistence within target ocular tissues is difficult. Distinguishing transplanted mitochondria from endogenous host mitochondria in vivo is challenging, particularly over extended periods following transplantation. Current preclinical studies rely on fluorescent labeling systems and quantum dot tracking to monitor mitochondrial trafficking, integration, and long-term metabolic contribution within recipient cells. Improved imaging modalities and real-time tracking technologies may become essential tools for validating therapeutic efficacy.
Although MSCs have low-immunogenicity, introduction of “naked” exogenous mitochondria may trigger a localized inflammatory response. MtDNA and cardiolipin can act as damage-associated molecular patterns (DAMPs) that activate innate immune signaling pathways [84]. Hence, decreasing inflammatory recognition of transplanted mitochondria is an important objective. One emerging strategy involves utilizing MSC-derived EVs as a delivery system capable of shielding mitochondria from immune surveillance while simultaneously improving cellular uptake and tissue targeting.
Mitochondrial transplantation faces a complex regulatory landscape. Determining whether isolated mitochondria should be classified as a biological, cellular therapy, or tissue-derived product under FDA and EMA frameworks remains unclear. Large-scale clinical translation requires establishing standards for manufacturing practices, donor screening protocols, sterility validation, and long-term safety monitoring guidelines. The relative accessibility and autologous potential of MSC-derived mitochondria may simplify certain ethical considerations compared to embryonic stem cell-based approaches (Figure 3). However, rigorous evaluation of long-term immunologic and metabolic consequences will still be necessary prior to widespread clinical adoption.
In sum, while the ocular tissues are characterized by easy accessibility, the transition of mitochondrial transplantation from an experimental concept to a clinically viable therapy for ocular trauma will require overcoming substantial challenges. Despite these limitations, continued advances in mitochondrial preservation technologies, bioengineering strategies, and organelle tracking systems suggest that many of these barriers are addressable in the near future. As manufacturing protocols become increasingly standardized and our understanding deepens, mitochondrial transplantation using autologous source to sidestep immune rejection could evolve from an experimental rescue strategy into a reproducible platform for regenerative ophthalmology.
While proof-of-concept studies in corneal, retinal, and optic nerve models provide encouraging early data, mitochondrial transplantation remains a preclinical technology in ophthalmology. Current evidence supports mechanistic plausibility and therapeutic potential; however, rigorous studies addressing dosing, delivery routes, long-term mitochondrial engraftment, safety, and clinical efficacy are required before translation into routine ocular regenerative therapies.